Ionis Pharmaceuticals and Akcea Therapeutics a wholly-owned subsidiary of Ionis, have entered a collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx. Ionis and Akcea are eligible to receive $225 million in near-term payments, including an immediate $75 million up-front option payment and a $100 million equity investment in Ionis. Ionis and Akcea are also eligible to receive a license fee as well as development, regulatory and commercial milest...